The wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer

Journal of Cellular Biochemistry

Volumn 113, Issue 1, 2012, Pages 13-18

  King, Taj D ^a   Suto, Mark J ^a   Li, Yonghe ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

LRP6, FRIZZLED 7; Therapeutic target; Triple negative breast cancer; Wnt catenin signaling

Indexed keywords

BETA CATENIN; FRIZZLED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; PROTEIN R SPONDIN; PROTEIN WIF1; REGULATOR PROTEIN; SALINOMYCIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; EMBRYO DEVELOPMENT; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STEM CELL; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; FRIZZLED RECEPTORS; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; PYRANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; WNT SIGNALING PATHWAY;

EID: 84055222589     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23350     Document Type: Article

References (48)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988. (Pubitemid 36418143)
2. Badders NM, Goel S, Clark RJ, Klos KS, Kim S, Bafico A, Lindvall C, Williams BO, Alexander CM,. 2009. The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. PLoS One 4: e6594.
3. Björklund P, Svedlund J, Olsson AK, Akerström G, Westin G,. 2009. The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS One 4: e4243.
4. Carey L, Winer E, Viale G, Cameron D, Gianni L,. 2010. Triple-negative breast cancer: Disease entity or title of convenience? Nat Rev Clin Oncol 7: 683-692.
5. Carmon KS, Gong X, Lin Q, Thomas A, Liu Q,. 2011. R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/β-catenin signaling. Proc Natl Acad Sci USA 108: 11452-11457.
6. de Lau W, Barker N, Low TY, Koo BK, Li VS, Teunissen H, Kujala P, Haegebarth A, Peters PJ, van de Wetering M, Stange DE, van Es J, Guardavaccaro D, Schasfoort RB, Mohri Y, Nishimori K, Mohammed S, Heck AJ, Clevers H,. 2011. Lgr5 homologuesassociate with Wnt receptors and mediate R-spondin signalling. Nature 476: 293-297.
7. Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, Bilic S, Ostrom L, Mosher R, Hartlepp KF, Zhu Z, Fawell S, Yao YM, Stover D, Finan PM, Porter JA, Sellers WR, Klagge IM, Cong F,. 2010. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA 107: 15473-15478.
8. Gattelli A, Zimberlin MN, Meiss RP, Castilla LH, Kordon EC,. 2006. Selection of early- occurring mutations dictates hormone-independent progression in mouse mammary tumor lines. J Virol 80: 11409-11415. (Pubitemid 44706583)
9. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS,. 2011. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24: 209-231.
10. Gong Y, Bourhis E, Chiu C, Stawicki S, DeAlmeida VI, Liu BY, Phamluong K, Cao TC, Carano RA, Ernst JA, Solloway M, Rubinfeld B, Hannoush RN, Wu Y, Polakis P, Costa M,. 2010. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One 5: e12682.
11. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES,. 2009. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659.
12. - phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53.
13. Howe LR, Brown AM,. 2004. Wnt signaling and breast cancer. Cancer Biol Ther 3: 36-41.
14. Jönsson M, Borg A, Nilbert M, Andersson T,. 2000. Involvement of adenomatous polyposis coli (APC)/β-catenin signalling in human breast cancer. Eur J Cancer 36 (2): 242-248. (Pubitemid 30102202)
15. Kazanskaya O, Glinka A, del Barco Barrantes I, Stannek P, Niehrs C, Wu W,. 2004. R-Spondin2 is a secreted activator of Wnt/β-catenin signaling and is required for Xenopus myogenesis. Dev Cell 7: 525-534. (Pubitemid 39341838)
16. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH,. 2010. Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176: 2911-2920.
17. Kikuchi A, Yamamoto H, Kishida S,. 2007. Multiplicity of the interactions of Wnt proteins and their receptors. Cell Signal 19: 659-671. (Pubitemid 46275377)
18. Kim KA, Kakitani M, Zhao J, Oshima T, Tang T, Binnerts M, Liu Y, Boyle B, Park E, Emtage P, Funk WD, Tomizuka K,. 2005. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science 309: 256-1259.
19. Kim KA, Zhao J, Andarmani S, Kakitani M, Oshima T, Binnerts ME, Abo A, Tomizuka K, Funk WD,. 2006. R-Spondin proteins: A novel link to β-catenin activation. Cell Cycle 5: 23-26.
20. Klarmann GJ, Decker A, Farrar WL,. 2008. Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 3: 59-63.
21. Klauzinska M, Baljinnyam B, Raafat A, Rodriguez-Canales J, Strizzi L, Greer YE, Rubin JS, Callahan R,. 2011. Rspo2/Int7 regulates invasiveness and tumorigenicproperties of mammary epithelial cells. J Cell Physiol [Epub ahead of print] PubMed PMID: 21732367.
22. Li Y, Chen J, Lu W, McCormick LM, Wang J, Bu G,. 2005. Mesd binds to mature LDL-receptor related protein-6 and antagonizes ligand binding. J Cell Sci 118: 5305-5314. (Pubitemid 41819592)
23. Li Y, Lu W, King TD, Liu CC, Bijur GN, Bu G,. 2010. Dkk1 stabilizes Wnt co-receptor LRP6: Implication for Wnt ligand-induced LRP6 down-regulation. PLoS One 5: e11014.
24. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC,. 2000. β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97: 4262-4266. (Pubitemid 30226121)
25. Lindvall C, Evans NC, Zylstra CR, Li Y, Alexander CM, Williams BO,. 2006. The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J Biol Chem 281: 35081-35087. (Pubitemid 46036547)
26. Lindvall C, Zylstra CR, Evans N, West RA, Dykema K, Furge KA, Williams BO,. 2009. The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development. PLoS One 4: e5813.
27. Liu CC, Prior J, Piwnica-Worms D, Bu G,. 2010. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA 107: 5136-5141.
28. Lowther W, Wiley K, Smith GH, Callahan R,. 2005. A new common integration site, Int7, for the mouse mammary tumor virus in mouse mammary tumors identifies a gene whose product has furin-like and thrombospondin-like sequences. J Virol 79: 10093-10096. (Pubitemid 41022354)
29. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA,. 2011. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA 108: 13253-13257.
30. Lu W, Liu CC, Thottassery JV, Bu G, Li Y,. 2010. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/β-catenin signaling in cancer cells. Biochemistry 49: 4635-4643.
31. MacDonald BT, Tamai K, He X,. 2009. Wnt/β-catenin signaling: Components, mechanisms, and diseases. Dev Cell 17: 9-26.
32. Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE,. 2009. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppressesMDA-MB-231 xenograft growth. Breast Cancer Res 11: R32.
33. Nam JS, Turcotte TJ, Yoon JK,. 2006. Dynamic expression of R-spondin family genes in mouse development. Gene Expr Patterns 7: 306-312.
34. Nusse R,. 2008. Wnt signaling and stem cell control. Cell Res 18: 523-527. (Pubitemid 351630946)
35. Polakis P,. 2007. The many ways of Wnt in cancer. Curr Opin Genet Dev 17: 45-51. (Pubitemid 46109296)
36. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG,. 2005. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511. (Pubitemid 40911148)
37. Prosperi JR, Goss KH,. 2010. A Wnt-ow of opportunity: Targeting the Wnt/β-catenin pathway in breast cancer. Curr Drug Targets 11: 1074-1088.
38. Reya T, Clevers H,. 2005. Wnt signalling in stem cells and cancer. Nature 434: 843-850. (Pubitemid 40558990)
39. Shimizu H, Julius MA, Giarré M, Zheng Z, Brown AM, Kitajewski J,. 1997. Transformation by Wnt family proteins correlates with regulation of β-catenin. Cell Growth Differ 8: 1349-1358. (Pubitemid 28008731)
40. Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, Mori M, Hirata K, Imai K, Shinomura Y, Baylin SB, Tokino T,. 2008. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 98: 1147-1156. (Pubitemid 351399804)
41. Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ, Zou CY, Xie XB, Zeng YX, Shen JN, Kang T, Wang J,. 2011. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett [Epub ahead of print].
42. Teissedre B, Pinderhughes A, Incassati A, Hatsell SJ, Hiremath M, Cowin P,. 2009. MMTV-Wnt1 and -ΔN89β-catenin induce canonical signaling in distinctprogenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS One 4: e4537.
43. Theodorou V, Kimm MA, Boer M, Wessels L, Theelen W, Jonkers J, Hilkens J,. 2007. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet 39: 759-769. (Pubitemid 46848585)
44. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE,. 1988. Expression of theint-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55: 619-625.
45. Wei Q, Yokota C, Semenov MV, Doble B, Woodgett J, He X,. 2007. R-spondin1 is a high affinity ligand for LRP6 and induces LRP6 phosphorylation and β-catenin signaling. J Biol Chem 282: 15903-15911. (Pubitemid 47093310)
46. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM,. 2007. WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104: 618-623. (Pubitemid 46123074)
47. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S, Somlo G, Yen Y,. 2011. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene [Epub ahead of print].
48. Zhang J, Li Y, Liu Q, Lu W, Bu G,. 2010. Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: Implication for breast cancer tumorigenesis. Oncogene 29: 539-549.